BPTH - Bio-Path Holdings, Inc.
| Previous Close | 0.52 |
| Open | 0.55 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 0.52 - 0.56 |
| 52 Week Range | 0.43 - 4.50 |
| Volume | 61,931 |
| Avg. Volume | 194,664 |
| Market Cap | 7.453M |
| Beta (3Y Monthly) | 2.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings Date | Nov 7, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- Simply Wall St.•14 days ago
What does Bio-Path Holdings Inc’s (NASDAQ:BPTH) Balance Sheet Tell Us About Its Future?
The direct benefit for Bio-Path Holdings Inc (NASDAQ:BPTH), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
- GlobeNewswire•28 days ago
Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering
HOUSTON, Sept. 25, 2018 -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle.
- GlobeNewswire•last month
Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering
Bio-Path will issue to the investors warrants to purchase up to 2,261,538 shares of common stock, which represents 100% of the number of shares of common stock issued in the registered direct offering, with an exercise price $0.96 per share and exercise period commencing six (6) months following the issuance date and a term of five and one-half (5.5) years. Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes.
- GlobeNewswire•2 months ago
Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference
HOUSTON, Aug. 29, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...
- GlobeNewswire•2 months ago
Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it has commenced Stage 2 of the company’s Phase 2 trial of prexigebersen in acute myeloid leukemia. “We are delighted to announce the expansion of our ongoing Phase 2 clinical trial of prexigebersen for the treatment of acute myeloid leukemia using a dosing schedule that administers a greater amount of prexigebersen to the patient prior to commencing LDAC dosing than in the first part of the trial.
- GlobeNewswire•2 months ago
Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Jason B. Fleming, M.D., F.A.C.S., to its Scientific Advisory Board (SAB). “We are thrilled to welcome Dr. Fleming to our scientific advisory board. As a leader in the treatment of gastrointestinal cancers, Dr. Fleming will be able to offer substantial insight as we seek to advance our lead drug candidate prexigebersen and our third drug candidate, BP1003, towards the clinic for the treatment of pancreatic cancer,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path.
- Associated Press•2 months ago
Bio-Path: 2Q Earnings Snapshot
The Bellaire, Texas-based company said it had a loss of 15 cents per share. The company's shares closed at $1.41. A year ago, they were trading at $3. _____ This story was generated by Automated Insights ...
- GlobeNewswire•2 months ago
Bio-Path Holdings Reports Second Quarter 2018 Financial Results
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2018 and provided an update on recent corporate developments. “During the second quarter we have continued to advance our corporate mission to develop RNAi nanoparticle drugs for cancer patients with high unmet medical need. Earlier studies showed 47% of evaluable patients demonstrated some degree of response to prexigebersen in combination with LDAC in this patient population, which is supportive of our Phase 2 clinical development program.
- ACCESSWIRE•2 months ago
Bio-Path Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 15, 2018 / Bio-Path Holdings, Inc. (NASDAQ: BPTH ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 15, 2018 at 8:30 AM Eastern ...
- GlobeNewswire•3 months ago
Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018
HOUSTON, Aug. 08, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...
- ACCESSWIRE•4 months ago
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
DALLAS, TX / ACCESSWIRE / June 26, 2018 / Bio-Path Holdings, Inc. ("Bio-Path") (NASDAQ: BPTH): COMPANY DESCRIPTION Bio-Path Holdings, Inc. (Bio-Path) is a clinical-stage biotechnology company ...
- Simply Wall St.•5 months ago
With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...
- Associated Press•5 months ago
Bio-Path: 1Q Earnings Snapshot
The Bellaire, Texas-based company said it had a loss of 17 cents per share. The company's shares closed at $1.76. A year ago, they were trading at $5.31. _____ This story was generated by Automated Insights ...
- ACCESSWIRE•7 months ago
Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you ...
- Zacks•7 months ago
Bio-Path Leukemia Combo Study Shows Positive Early Data
Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.
- InvestorPlace•7 months ago
Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today
The other bit of good news for BPTH stock today was financial results for its fiscal full year of 2017. During the year, the company reported a net loss of $8.1 million, or 80 cents per share. This is a wider net loss than the $6.8 million, or 73 cents per share from the year prior.
- Benzinga•7 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Long Blockchain Corp (NASDAQ: LBCC ) stock gained ...
- ACCESSWIRE•7 months ago
Bio-Path Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Bio-Path Holdings, Inc. (NASDAQ: BPTH ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 3, 2018 at 8:30 AM Eastern Time. ...
